Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Change in Accured Expenses: 2012-2025

Historic Change in Accured Expenses for Veracyte (VCYT) over the last 13 years, with Sep 2025 value amounting to $9.1 million.

  • Veracyte's Change in Accured Expenses rose 45525.00% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 1.01%. This contributed to the annual value of $3.5 million for FY2024, which is 623.82% up from last year.
  • As of Q3 2025, Veracyte's Change in Accured Expenses stood at $9.1 million, which was up 34.23% from $6.8 million recorded in Q2 2025.
  • Veracyte's Change in Accured Expenses' 5-year high stood at $12.9 million during Q2 2024, with a 5-year trough of -$9.0 million in Q1 2024.
  • For the 3-year period, Veracyte's Change in Accured Expenses averaged around $899,909, with its median value being $334,000 (2023).
  • As far as peak fluctuations go, Veracyte's Change in Accured Expenses plummeted by 1,879.74% in 2023, and later spiked by 45,525.00% in 2025.
  • Over the past 5 years, Veracyte's Change in Accured Expenses (Quarterly) stood at $11.1 million in 2021, then crashed by 81.02% to $2.1 million in 2022, then grew by 29.34% to $2.7 million in 2023, then tumbled by 112.89% to -$351,000 in 2024, then soared by 45,525.00% to $9.1 million in 2025.
  • Its last three reported values are $9.1 million in Q3 2025, $6.8 million for Q2 2025, and -$8.9 million during Q1 2025.